Drug reference
tepotinib
MET kinase inhibitor · Antineoplastic agent
MET kinase inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
D
FDA category + note
Mechanism
Tepotinib is an orally bioavailable inhibitor of the MET kinase.
Indications
metastatic NSCLC with a mutation that leads to MET exon 14 skipping
Pharmacokinetics
Half-life
32 h
Metabolism
CYP3A4 (predominantly)
Side effects
Common
peripheral edemadyspepsiafatiguemusculoskeletal pain
Pregnancy & lactation
Pregnancy
D
Related guidelines
Other MET kinase inhibitor drugs
Ask House about tepotinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team